Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 8/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | EP300 | Q09472 | 1/20 | 0.32 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9910083 | 0.90 | CA1 (0.36) | RXFP1KDM4EMAPK1METALDH1A1 | |
| SCHEMBL2698259 | 0.84 | RXFP1 (0.32) | RXFP1KDM4EMAPK1METALDH1A1 | |
| SCHEMBL2698255 | 0.83 | RXFP1 (0.34) | RXFP1KDM4EMAPK1ALDH1A1SMN1; SMN2 | |
| SCHEMBL2697765 | 0.82 | RXFP1 (0.34) | RXFP1KDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL2698083 | 0.76 | MET (0.53) | KDM4EMAPK1METALDH1A1SMN1; SMN2 | |
| SCHEMBL20857107 | 0.67 | KMT2A (0.45) | KDM4EALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6608326 | 0.66 | HDAC3 (0.42) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL14291333 | 0.66 | MEN1 (0.43) | ALDH1A1HPGDKMT2AMEN1EP300 | |
| SCHEMBL6167181 | 0.65 | PDE7A (0.43) | ALDH1A1SMN1; SMN2HPGDKMT2AMEN1 | |
| SCHEMBL2695922 | 0.64 | MET (0.63) | KDM4EMETSMN1; SMN2TRPC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3093289-A1 | [1,2,4]TRIAZOLO[4,3-A]PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR | Amgen, Inc (US) | 2016-11-16 | — | — | EP | disclosed |
| EP-2081931-B1 | [1,2,4]Triazolo[4,3-a]pyridine derivatives useful as inhibitors of the hepatocyte growth factor receptor | AMGEN INC (US) | 2016-08-31 | — | — | EP | disclosed |
| US-9066954-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2015-06-30 | — | — | US | disclosed |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC (US) | 2013-11-14 | — | — | US | disclosed |
| US-8524900-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2013-09-03 | — | — | US | disclosed |
| EP-2578583-A1 | Fused heterocyclic derivatives and methods of use | Amgen Inc. (US) | 2013-04-10 | — | — | EP | disclosed |
| US-8217177-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-10 | — | — | US | disclosed |
| US-8212041-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-07-03 | — | — | US | disclosed |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-8198448-B2 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | AMGEN INC. (US) | 2009-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318436-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
| US-20120148531-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
| US-20090124612-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
| US-20130303529-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
| US-20090124609-A1 | Fused heterocyclic derivatives and methods of use | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
| US-20120107275-A1 | FUSED HETEROCYCLIC DERIVATIVES AND METHODS OF USE | HGF, HGFAC, MET | RXFP1 3771/4885KDM4E 4500/4885MAPK1 2550/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.